Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models

Toxicol In Vitro. 2021 Apr:72:105096. doi: 10.1016/j.tiv.2021.105096. Epub 2021 Jan 16.

Abstract

Inhibition of dihydroorotate dehydrogenase (DHODH), the rate-limiting enzymatic step in de novo pyrimidine synthesis, has broad immunosuppressive effects in vivo and shows promise as a therapeutic target for the treatment of malignancies, viral infections and auto-immune diseases. Whilst there are numerous DHODH inhibitors under development, leflunomide and teriflunomide are the only FDA approved compounds on the market, each of which have been issued with black-box warnings for hepatotoxicity. Mitochondrial dysfunction is a putative mechanism by which teriflunomide and leflunomide elicit their hepatotoxic effects, however it is as yet unclear whether this is shared by other nascent DHODH inhibitors. The present study aimed to evaluate the propensity for DHODH inhibitors to mediate mitochondrial dysfunction in two hepatic in vitro models. Initial comparisons of cytotoxicity and ATP content in HepaRG® cells primed for oxidative metabolism, in tandem with mechanistic evaluations by extracellular flux analysis identified multifactorial toxicity and moderate indications of respiratory chain dysfunction or uncoupling. Further investigations using HepG2 cells, a hepatic line with limited capability for phase I xenobiotic metabolism, identified leflunomide and brequinar as positive mitochondrial toxicants. Taken together, biotransformation of some DHODH inhibitor species may play a role in mediating or masking hepatic mitochondrial liabilities.

Keywords: DILI; Dihydroorotate dehydrogenase; Dysfunction; HepG2; HepaRG®; Mitochondria.

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Antineoplastic Agents / toxicity*
  • Biphenyl Compounds / toxicity
  • Cell Line
  • Cell Respiration / drug effects
  • Crotonates / toxicity
  • Dicarboxylic Acids / toxicity
  • Dihydroorotate Dehydrogenase
  • Humans
  • Hydroxybutyrates / toxicity
  • Immunosuppressive Agents / toxicity*
  • Leflunomide / toxicity
  • Liver / drug effects*
  • Liver / metabolism
  • Mitochondria / drug effects*
  • Mitochondria / metabolism
  • Models, Biological
  • Nitriles / toxicity
  • Oxidoreductases Acting on CH-CH Group Donors / antagonists & inhibitors*
  • Salicylanilides / toxicity
  • Toluidines / toxicity
  • Triazoles / toxicity

Substances

  • Antineoplastic Agents
  • Biphenyl Compounds
  • Crotonates
  • Dicarboxylic Acids
  • Dihydroorotate Dehydrogenase
  • Hydroxybutyrates
  • Immunosuppressive Agents
  • Nitriles
  • Salicylanilides
  • Toluidines
  • Triazoles
  • teriflunomide
  • brequinar
  • Adenosine Triphosphate
  • vidofludimus
  • Oxidoreductases Acting on CH-CH Group Donors
  • Leflunomide
  • orludodstat